Muscimol, a potent GABAA receptor agonist and psychoactive alkaloid found in Amanita mushrooms, is widely used as a tool compound in neurochemical research. Despite its importance, synthetic access to [3H]muscimol of high specific activity has remained limited due to the challenges associated with conventional labeling strategies. Herein, we report a novel synthetic approach for the preparation of [3H]muscimol based on the reduction of a suitably protected amide precursor using in situ generated tritioborane (BT3·THF). The precursor was synthesized in four steps from dimethyl acetylenedicarboxylate, and subsequent electrophilic reduction afforded [3H]benzyl-protected muscimol in a radiochemical yield of 44 mCi (1.63 GBq) and a molar activity of 48.3 Ci/mmol (1.79 TBq/mmol). Final deprotection with HBr in acetic acid yielded [3H]muscimol·HBr in > 95% radiochemical purity. The method avoids the use of bulk tritiated water employed in established synthetic protocols and enables safe, reliable, and efficient access to this valuable radioligand for applications in GABA receptor studies.

Institute of Organic Chemistry and Biochemistry Czech Academy of Sciences Prague Czechia

Zobrazit více v PubMed

Bowden K. and Drysdale A. C., “A Novel Constituent of PubMed DOI

Munro G., Hansen R. R., and Mirza N. R., “GABA(A) Receptor Modulation: Potential to Deliver Novel Pain Medicines?,” European Journal of Pharmacology 716, no. 1‐3 (2013): 17–23, 10.1016/j.ejphar.2013.01.070. PubMed DOI

Johnston G. A. R., “Muscimol as an Ionotropic GABA Receptor Agonist,” Neurochemical Research 39, no. 10 (2014): 1942–1947, 10.1007/s11064-014-1245-y. PubMed DOI

Frolund B., Ebert B., Kristiansen U., Liljefors T., and Krogsgaard‐Larsen P., “GABA‐A Receptor Ligands and Their Therapeutic Potentials,” Current Topics in Medicinal Chemistry 2, no. 8 (2005): 817–832, 10.2174/1568026023393525. PubMed DOI

den Hartigh A. B., Loomis W. P., Anderson M. J., Frølund B., and Fink S. L., “Muscimol Inhibits Plasma Membrane Rupture and Ninjurin‐1 Oligomerization During Pyroptosis,” Communications Biology 6, no. 1 (2023): 1–12, 10.1038/s42003-023-05354-4. PubMed DOI PMC

Liu G., Ozoe F., Furuta K., and Ozoe Y., “4,5‐Substituted 3‐Isoxazolols With Insecticidal Activity Act as Competitive Antagonists of Housefly GABA Receptors,” Journal of Agricultural and Food Chemistry 63, no. 28 (2015): 6304–6312, 10.1021/acs.jafc.5b01843. PubMed DOI

Ramawad H. A., Paridari P., Jabermoradi S., et al., “Muscimol as a Treatment for Nerve Injury‐Related Neuropathic Pain: A Systematic Review and Meta‐Analysis of Preclinical Studies,” Korean Journal of Pain 36, no. 4 (2023): 425–440, 10.3344/kjp.23161. PubMed DOI PMC

Osborne N. N., “Binding of [3H]‐Muscimol, a Potent Γ‐Aminobutyric Acid Receptor Agonist, to Membranes of the Bovine Retina,” British Journal of Pharmacology 71, no. 1 (1980): 259–264, 10.1111/j.1476-5381.1980.tb10934.x. PubMed DOI PMC

Beaumont K., Chilton W. S., Yamamura H. I., and Enna S. J., “Muscimol Binding in Rat Brain: Association With Synaptic GABA Receptors,” Brain Research 148 (1978): 153–162. PubMed

Snodgrass R. S., “Use of PubMed

Rivera‐Illanes D. and Recabarren‐Gajardo G., “Classics in Chemical Neuroscience: Muscimol,” ACS Chemical Neuroscience 15, no. 18 (2024): 3257–3269, 10.1021/acschemneuro.4c00304. PubMed DOI

Wellendorph P., Hog S., Greenwood J. R., et al., “Cyclic γ‐Hydroxybutyrate (GHB) Analogs With High Affinity and Stereoselectivity of Binding to GHB Sites in Rat Brain,” Journal of Pharmacology and Experimental Therapeutics 315, no. 1 (2005): 346–351. PubMed

Smith G. B. and Olsen R. W., “Identification of a [3H]Muscimol Photoaffinity Substrate in the Bovine Gamma‐Aminobutyric AcidA Receptor Alpha Subunit,” Journal of Biological Chemistry 269, no. 32 (1994): 20380–20387, 10.1016/s0021-9258(17)32003-3. PubMed DOI

Browning M. D., Bureau M., Dudek E. M., and Olsen R. W., “Protein Kinase C and cAMP‐Dependent Protein Kinase Phosphorylate the f8 Subunit of the Purified y‐Aminobutyric Acid A Receptor,” Proceedings of the National Academy of Science USA 87 (1990): 1315–1318. PubMed PMC

Krogsgaard‐Larsen P., Frølund B., and Frydenvang K., “GABA Uptake Inhibitors. Design, Molecular Pharmacology and Therapeutic Aspects,” Current Pharmaceutical Design 6 (2000): 1193–1209. PubMed

Filer C. N., “GABAergic Radioligands Labelled With Tritium,” Journal of Labelled Compounds and Radiopharmaceuticals 53, no. 3 (2010): 120–129, 10.1002/jlcr.1737. DOI

Filer C. N., Lacy J. M., and Peng C. T., “Ibotenic Acid Decarboxylation to Muscimol: Dramatic Solvent and Radiolytic Rate Acceleration,” Synthetic Communications 35, no. 7 (2005): 967–970, 10.1081/SCC-200051704. DOI

Filer C. N., “Ibotenic Acid: On the Mechanism of Its Conversion to [ DOI

Morimoto H. and Williams P. G., “Design and Operations at the National Tritium Labelling Facility,” Fusion Technology 21, no. 2P2 (1992): 256–261, 10.13182/fst92-a29754. DOI

Welch W. M., “A Shorter Synthesis of Muscimol,” Synthetic Communications 12, no. 14 (1982): 1089–1092, 10.1080/00397919308020392. DOI

Jäger V. and Frey M., “A Short Synthesis of Muscimol,” Liebigs Annalen Der Chemie 1982, no. 4 (1982): 817–820, 10.1002/jlac.198219820423. DOI

Pevarello P. and Varasi M., “An Improved Synthesis of Muscimol,” Synthetic Communications 22, no. 13 (1992): 1939–1948.

Garmestani K., Link J. M., and Krohn K. A., “Synthesis of Tritiated Diborane and Cryptand [2.2.2],” Journal of Labelled Compounds & Radiopharmaceuticals 28, no. 10 (1990): 1171–1178, 10.1002/jlcr.2580281009. DOI

Taylor G. F., Thornton S. S., Tallent C. R., and Kepler J. A., “[3″‐3H]Taxol and [13‐3H]Taxol,” Journal of Labelled Compounds and Radiopharmaceuticals 33, no. 6 (1993): 501–515.

Nugent R. P. and Filer C. N., “Generation and Use of Tritiated Borane In Situ for Formamide Tritiation to an N‐methyl‐3H Group,” Journal of Labelled Compounds & Radiopharmaceuticals 61, no. 10 (2018): 805–808, 10.1002/jlcr.3624. PubMed DOI

Brown W. G., Kaplan L., and Wilzbach K. E., “The Exchange of Hydrogen Gas With Lithoum and Sodium Borohydrides,” Journal of American Chemical Society 1952, no. 1343 (1951): 1343–1344.

Than C., Morimoto H., Andres H., and Williams P. G., “Preparation, NMR Characterization, and Labeling Reactions of Tritiated Borane‐THF Complex at High Specific Radioactivity,” Journal of Organic Chemistry 60, no. 23 (1995): 7503–7507, 10.1021/jo00128a023. PubMed DOI

Marek A., Pedersen M. H. F., Vogensen S. B., Clausen R. P., Frølund B., and Elbert T., “The Labeling of Unsaturated γ‐Hydroxybutyric Acid by Heavy Isotopes of Hydrogen: Iridium Complex‐Mediated H/D Exchange by C─H Bond Activation vs Reduction by Boro‐Deuterides/Tritides,” Journal of Labelled Compounds and Radiopharmaceuticals 59, no. 16 (2016): 476–483, 10.1002/jlcr.3432. PubMed DOI

Furniss B. S., Hannaford A. J., Smith P. W. G., and Tatchell A. R., Vogel's Textbook of Practical Organic Cgemistry (Longman Scientific & Technical Longman House, 1989).

Zippi E. M., Morimoto H., Williams P. G., and Andres H., “Preparation and Use of Lithium Tritide and Lithium Trimethoxyborotritide,” Synthetic Communications 25, no. 17 (1995): 2685–2693, 10.1080/00397919508011815. DOI

Vogensen S. B., Marek A., Bay T., et al., “New Synthesis and Tritium Labeling of a Selective Ligand for Studying High‐Affinity Gamma‐Hydroxybutyrate (GHB) Binding Sites,” Journal of Medicinal Chemistry 56, no. 20 (2013): 8201–8205, 10.1021/jm4011719. PubMed DOI PMC

Kriegelstein M., Hojcskova J., Hroch M., and Marek A., “Direct Multi‐Deuterium Labelling of Pirtobrutinib,” Journal of Labelled Compounds & Radiopharmaceuticals 67, no. 9 (2024): 314–323, 10.1002/jlcr.4117. PubMed DOI

Saljoughian M., Morimoto H., and Williams P. G., “A General Synthesis of Very High Specific Activity Tritiomethyl Iodide,” Journal of the Chemical Society, Perkin Transactions 1, no. 6 (1990): 1803–1808, 10.1039/p19900001803. DOI

Kupka T., Broda M. A., and Wieczorek P. P., “What Is the Form of Muscimol From Fly Agaric Mushroom ( PubMed DOI